The impact of prior therapy with ketoconazole (keto) on clinical outcomes after subsequent docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) patients: Results from a randomized phase III trial (CALGB 90401)

被引：0
|
作者：
Small, Eric Jay
Halabi, Susan
Carducci, Michael Anthony
Ryan, Charles J.
George, Daniel J.
Mahoney, John Francis
Stadler, Walter Michael
Morris, Michael J.
Kantoff, Philip
Monk, J. P.
Kelly, William Kevin
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Duke Univ, Sch Med, Durham, NC USA
[3] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[4] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[5] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[6] Duke Canc Inst, Durham, NC USA
[7] Carolinas Hematol Oncol Associates, Charlotte, NC USA
[8] Univ Chicago, Chicago, IL 60637 USA
[9] Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY 10021 USA
[10] Dana Farber Canc Inst, Boston, MA 02115 USA
[11] Ohio State Univ, CALGB, Columbus, OH 43210 USA
[12] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4667
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure
    Meulenbeld, Hielke J.
    Bleuse, Jean P.
    Vinci, Elio M.
    Raymond, Eric
    Vitali, Giordano
    Santoro, Armando
    Dogliotti, Luigi
    Berardi, Rossana
    Cappuzzo, Federico
    Tagawa, Scott T.
    Sternberg, Cora N.
    Jannuzzo, Maria G.
    Mariani, Mariangela
    Petroccione, Anna
    de Wit, Ronald
    BJU INTERNATIONAL, 2013, 111 (01) : 44 - 52
  • [32] Impact of combined lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC)
    Mak, B.
    Lin, H-M.
    Kwan, E. M.
    Fettke, H.
    Tran, B.
    Davis, I. D.
    Mahon, K. L.
    Stockler, M. R.
    Briscoe, K.
    Marx, G. M.
    Kohli, M.
    Tan, W.
    Huynh, K.
    Du, P.
    Yu, J.
    Jia, S.
    Joshua, A. M.
    Azad, A. A.
    Meikle, P. J.
    Horvath, L. G.
    ANNALS OF ONCOLOGY, 2021, 32 : S642 - S643
  • [33] Impact of body composition parameters on clinical outcomes in patients with metastatic castration-resistant prostate cancer treated with docetaxel
    Power, Derek Gerard
    Cushen, Samantha
    McDermott, Ray
    Lim, Marvin Chang Jui
    Mceneaney, Peter
    Daly, Louise
    Griffin, Brendan
    Murphy, Kevin P.
    Ryan, Aoife M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer
    Oudard, Stephane
    FUTURE ONCOLOGY, 2011, 7 (04) : 497 - 506
  • [35] The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer
    Schweizer, Michael T.
    Zhou, Xian C.
    Wang, Hao
    Bassi, Sunakshi
    Carducci, Michael A.
    Eisenberger, Mario A.
    Antonarakis, Emmanuel S.
    EUROPEAN UROLOGY, 2014, 66 (04) : 646 - 652
  • [36] ORAL METRONOMIC CYCLOPHOSPHAMIDE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER STRATIFIED BY PRIOR DOCETAXEL THERAPY
    Barroso-Sousa, R.
    Chaves, A. C. R.
    Fonseca, L. G.
    De Castro, G., Jr.
    Dzik, C.
    Hoff, P. M.
    ANNALS OF ONCOLOGY, 2012, 23 : 308 - 308
  • [37] Outcomes of first subsequent taxane (FST) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who previously received docetaxel intensification (DI) for metastatic castration-sensitive prostate cancer (mCSPC).
    Robin, Gabrielle
    Basappa, Naveen S.
    North, Scott A.
    Ghosh, Sunita
    Kolinsky, Michael Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [38] PHASE 2 TRIAL OF A DNA VACCINE WITH PEMBROLIZUMAB IN PATIENTS WITH METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    McNeel, Douglas
    Eickhoff, Jens
    Wargowski, Ellen
    Johnson, Laura
    Kyriakopoulos, Christos
    Emamekhoo, Hamid
    Lang, Joshua
    Brennan, Mary Jane
    Liu, Glenn
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A377 - A377
  • [39] Phase I trial with a combination of docetaxel and 153Sm- EDTMP in patients (pts) with castration-resistant metastatic prostate cancer (mCRPC)
    Eisenberger, M. A.
    Lin, J.
    Sinibaldi, V. J.
    Carducci, M. A.
    Denmeade, S.
    DeWeese, T.
    Song, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] A phase II study of sunitinib (SU) for maintenance therapy in metastatic castration-resistant prostate cancer (mCRPC) after response to docetaxel (D)
    Eigl, B. J.
    Trudeau, M. G.
    Winquist, E.
    Chi, K. N.
    Eliasziw, M.
    North, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
12345